Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2015

Conditions
Urinary Bladder NeoplasmsUrologic NeoplasmsNeoplasmsUrinary Bladder DiseasesUrologic Diseases
Interventions
DEVICE

40 mg MMC in 40 mL TC-3.

A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.

DEVICE

80 mg MMC in 40 mL TC-3.

A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.

Trial Locations (1)

110085

Rajiv Gandhi Cancer Institute & Research Center, Delhi

All Listed Sponsors
lead

UroGen Pharma Ltd.

INDUSTRY

NCT02891460 - Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients | Biotech Hunter | Biotech Hunter